Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Intraperitoneal (IP) Plus Intravenous (IV) Chemotherapy Versus IV Carboplatin Plus Paclitaxel in Patients With Epithelial Ovarian Cancer Optimally Debulked at Surgery Following Neoadjuvant Intravenous Chemotherapy

NCT00993655 is registered in ClinicalTrials.gov with Canadian Cancer Trials Group as lead sponsor.

NCT NCT00993655
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00993655 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Intraperitoneal (IP) Plus Intravenous (IV) Chemotherapy Versus IV Carboplatin Plus Paclitaxel in Patients With Epithelial Ovarian Cancer Optimally Debulked at Surgery Following Neoadjuvant Intravenous Chemotherapy
Lead sponsor
Canadian Cancer Trials Group
Phase
Phase 2
Overall status
Completed
Start date
March 3, 2010
Completion date
July 11, 2016
Enrollment
275 (actual)
Sites
50

Conditions

As the registry lists them; a condition with its own page is linked.

fallopian tube cancer, metastatic cancer, ovarian cancer, peritoneal cavity cancer